By Josh Beckerman
Shares of Tivic Health Systems rose after it discussed briefings provided to senior leadership at the White House and Food and Drug Administration about potential military and defense uses of its product candidates.
The stock was recently up 104% to $7.13 Tuesday. Its intraday range was $6.61 to $13.23. Volume was more than 30.8 million shares, compared with a 65-day average of 1.2 million. Shares are up about 20% this year.
The White House briefing involved the company's TLR5 program, including lead product candidate Entolimod, and the need for advanced treatments for acute radiation syndrome, Tivic said.
The meeting with FDA leadership explored expedited pathways to approval for Entolimod and Entolasta, the company said.
Tivic Chief Operating Officer and President Michael Handley said, "We believe that Entolimod, in particular, is well positioned to fill a critical gap in treating exposure to ionizing radiation and offers several potential advantages over existing approved drugs in the category."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 22, 2025 13:11 ET (17:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。